Annual ROE
425.33%
+613.14%+326.47%
31 December 2023
Summary:
CNS Pharmaceuticals annual return on equity is currently 425.33%, with the most recent change of +613.14% (+326.47%) on 31 December 2023. During the last 3 years, it has risen by +493.14% (+727.24%). CNSP annual ROE is now -68.39% below its all-time high of 1345.69%, reached on 31 December 2018.CNSP ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
695.91%
+267.00%+62.25%
30 September 2024
Summary:
CNS Pharmaceuticals quarterly return on equity is currently 695.91%, with the most recent change of +267.00% (+62.25%) on 30 September 2024. Over the past year, it has increased by +1299.33% (+215.33%). CNSP quarterly ROE is now -97.91% below its all-time high of 33.26 thousand%, reached on 31 December 2023.CNSP Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNSP ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +326.5% | +215.3% |
| 3 y3 years | +727.2% | +670.3% |
| 5 y5 years | -68.4% | -95.0% |
CNSP ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +280.9% | -97.9% | +215.3% |
| 5 y | 5 years | -68.4% | +280.9% | -97.9% | +215.3% |
| alltime | all time | -68.4% | +280.9% | -97.9% | +215.3% |
CNS Pharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 695.91%(+62.3%) |
| June 2024 | - | 428.91%(-50.0%) |
| Mar 2024 | - | 857.23%(-97.4%) |
| Dec 2023 | 425.33%(-326.5%) | 33.26 K%(-5612.2%) |
| Sept 2023 | - | -603.42%(+93.6%) |
| June 2023 | - | -311.66%(+44.1%) |
| Mar 2023 | - | -216.28%(+51.7%) |
| Dec 2022 | -187.81%(-20.1%) | -142.58%(+8.8%) |
| Sept 2022 | - | -131.02%(-1.2%) |
| June 2022 | - | -132.59%(+0.3%) |
| Mar 2022 | - | -132.16%(-11.3%) |
| Dec 2021 | -235.19% | -149.00%(+22.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | -122.03%(-1.7%) |
| June 2021 | - | -124.20%(-12.2%) |
| Mar 2021 | - | -141.49%(-2.7%) |
| Dec 2020 | -67.81%(+32.9%) | -145.38%(-20.4%) |
| Sept 2020 | - | -182.57%(+2.3%) |
| June 2020 | - | -178.50%(+9.7%) |
| Mar 2020 | - | -162.66%(+11.6%) |
| Dec 2019 | -51.01%(-103.8%) | -145.78%(-101.0%) |
| Sept 2019 | - | 13.97 K%(+60.5%) |
| June 2019 | - | 8703.85%(+555.5%) |
| Mar 2019 | - | 1327.82%(+3.0%) |
| Dec 2018 | 1345.69% | 1289.31% |
FAQ
- What is CNS Pharmaceuticals annual return on equity?
- What is the all time high annual ROE for CNS Pharmaceuticals?
- What is CNS Pharmaceuticals annual ROE year-on-year change?
- What is CNS Pharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for CNS Pharmaceuticals?
- What is CNS Pharmaceuticals quarterly ROE year-on-year change?
What is CNS Pharmaceuticals annual return on equity?
The current annual ROE of CNSP is 425.33%
What is the all time high annual ROE for CNS Pharmaceuticals?
CNS Pharmaceuticals all-time high annual return on equity is 1345.69%
What is CNS Pharmaceuticals annual ROE year-on-year change?
Over the past year, CNSP annual return on equity has changed by +613.14% (+326.47%)
What is CNS Pharmaceuticals quarterly return on equity?
The current quarterly ROE of CNSP is 695.91%
What is the all time high quarterly ROE for CNS Pharmaceuticals?
CNS Pharmaceuticals all-time high quarterly return on equity is 33.26 K%
What is CNS Pharmaceuticals quarterly ROE year-on-year change?
Over the past year, CNSP quarterly return on equity has changed by +1299.33% (+215.33%)